A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

Sumithira Vasu, Jessica K. Altman, Geoffrey L. Uy, Martin S. Tallman, Ivana Gojo, Gerard Lozanski, Ute Burkard, Annika Osswald, Pamela James, Björn Rüter, William Blum*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)770-773
Number of pages4
JournalHaematologica
Volume107
Issue number3
DOIs
StatePublished - Mar 2022

ASJC Scopus subject areas

  • Hematology

Cite this